| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1827 | 2020 |
| Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque ZD Drobni, RM Alvi, J Taron, A Zafar, SP Murphy, PK Rambarat, ... Circulation 142 (24), 2299-2311, 2020 | 318 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 285 | 2021 |
| Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with … MF Sanmamed, S Fernández-Landázuri, C Rodríguez, R Zárate, ... Clinical chemistry 61 (1), 297-304, 2015 | 274 | 2015 |
| The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors H Seethapathy, S Zhao, DF Chute, L Zubiri, Y Oppong, I Strohbehn, ... Clinical Journal of the American Society of Nephrology 14 (12), 1692-1700, 2019 | 221 | 2019 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| Circulating melanoma exosomes as diagnostic and prognosis biomarkers E Alegre, L Zubiri, JL Perez-Gracia, M González-Cao, L Soria, ... Clinica chimica acta 454, 28-32, 2016 | 167 | 2016 |
| Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor–Associated myocarditis L Zhang, DA Zlotoff, M Awadalla, SS Mahmood, A Nohria, MZO Hassan, ... Circulation 141 (24), 2031-2034, 2020 | 162 | 2020 |
| Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis A Faje, K Reynolds, L Zubiri, D Lawrence, JV Cohen, RJ Sullivan, ... European journal of endocrinology 181 (3), 211-219, 2019 | 133 | 2019 |
| Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors AC Guidon, LB Burton, BK Chwalisz, J Hillis, TH Schaller, AA Amato, ... Journal for immunotherapy of cancer 9 (7), 2021 | 112 | 2021 |
| Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study V Naranbhai, CA Pernat, A Gavralidis, KJ St Denis, EC Lam, LM Spring, ... Journal of Clinical Oncology 40 (1), 12, 2022 | 76 | 2022 |
| Association of cutaneous immune-related adverse events with increased survival in patients treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 therapy K Tang, J Seo, BC Tiu, TK Le, V Pahalyants, NS Raval, PO Ugwu-Dike, ... JAMA dermatology 158 (2), 189-193, 2022 | 74 | 2022 |
| Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors RK Leaf, C Ferreri, D Rangachari, J Mier, W Witteles, G Ansstas, ... American journal of hematology 94 (5), 563-574, 2019 | 62 | 2019 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 60 | 2021 |
| Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung … SD Criss, MJ Mooradian, DF Sheehan, L Zubiri, MA Lumish, JF Gainor, ... JAMA oncology 5 (3), 358-365, 2019 | 57 | 2019 |
| COVID-19 and Cancer Consortium NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study …, 2020 | 55 | 2020 |
| Liver biopsy findings in patients on immune checkpoint inhibitors JV Cohen, M Dougan, L Zubiri, KL Reynolds, RJ Sullivan, J Misdraji Modern Pathology 34 (2), 426-437, 2021 | 54 | 2021 |
| Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors H Seethapathy, S Zhao, IA Strohbehn, M Lee, DF Chute, H Bates, ... Kidney international reports 5 (10), 1700-1705, 2020 | 53 | 2020 |
| Circulating biomarkers in malignant melanoma E Alegre, M Sammamed, S Fernández-Landázuri, L Zubiri, Á González Advances in clinical chemistry 69, 47-89, 2015 | 53 | 2015 |
| Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims … M Kalinich, W Murphy, S Wongvibulsin, V Pahalyants, KH Yu, C Lu, ... Journal for immunotherapy of cancer 9 (3), 2021 | 50 | 2021 |
